title: More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial).
authors.affiliation: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Niki
authors.initials: N
authors.lastname: Katsiki
authors.affiliation: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece.
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.affiliation: Department of Clinical Biochemistry (Vascular Prevention Clinics), Royal Free Hospital Campus, University College Medical School, University College London, London, UK.
authors.forename: Dimitris P
authors.initials: DP
authors.lastname: Mikhailidis
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000069438:Ezetimibe / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000517:prevention & control*; D019821:Simvastatin / Q000008:administration & dosage*
chemical_list: D019821:Simvastatin; D000069438:Ezetimibe